Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized comparison of panitumumab versus cetuximab in chemorefractory wild-type KRAS metastatic colorectal cancer
2009-010715-32Phase 3Completed
- Sponsor
- Amgen
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in metastatic colorectal adenocarcinoma (mCRC) comparing Panitumumab with Cetuximab (2 arms). Primary endpoint: Overall survival. Started Oct 2009; status: completed.
02
Drugs
panitumumabcetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2009-010715-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010715-32.